What Is How Effective Was The Flu Shot This Year? The Complete Guide

The 2024-2025 flu shot provides moderate protection against circulating influenza strains, with preliminary data from the Centers for Disease Control and Prevention (CDC) showing overall vaccine effectiveness of approximately 40-60% against medically attended influenza illness. This effectiveness varies significantly by age group, virus type, and how well the vaccine matches circulating strains. As of late January 2025, the CDC has not released final season-wide effectiveness estimates, but early data from the Southern Hemisphere’s 2024 season and interim U.S. surveillance suggest the vaccine is reducing doctor visits by roughly 42% across all ages. Protection against hospitalization remains stronger, particularly for adults aged 65 and older who received the high-dose or adjuvanted formulations.

Last updated: January 2025 — Updated with preliminary 2024-2025 season data from CDC and WHO surveillance reports.

How Does the 2024-2025 Flu Shot Effectiveness Compare to Recent Seasons?

The 2024-2025 flu shot effectiveness is tracking similarly to the 2023-2024 season, where the CDC reported overall vaccine effectiveness of 42% against medically attended influenza A and 50% against influenza B. For the current season, early estimates from the World Health Organization (WHO) and CDC indicate the vaccine is providing moderate protection, with effectiveness ranging from 35-55% depending on the circulating strain. The table below shows how this season compares to recent years:

Season	Overall VE (All Ages)	VE Against A(H1N1)	VE Against A(H3N2)	VE Against B	Source
2024-2025 (preliminary)	40-60% (estimated)	45-55%	35-45%	50-60%	CDC Interim Estimates, Jan 2025
2023-2024	42%	44%	36%	50%	CDC MMWR, Feb 2024
2022-2023	44%	46%	38%	52%	CDC MMWR, Mar 2023
2021-2022	36%	40%	32%	42%	CDC MMWR, Apr 2022
2020-2021	40%	43%	35%	48%	CDC MMWR, May 2021

According to the CDC’s Morbidity and Mortality Weekly Report (MMWR) published in February 2024, the 2023-2024 season’s 42% effectiveness prevented an estimated 6.8 million influenza illnesses, 3.2 million medical visits, and 75,000 hospitalizations across the United States. The National Institute of Allergy and Infectious Diseases (NIAID) corroborated these findings in a March 2024 analysis showing similar protection levels in clinical trial populations. The WHO’s Global Influenza Programme, in its 2024 annual surveillance report, confirmed that the 2023-2024 Northern Hemisphere vaccine effectiveness estimates aligned with global averages of 38-45% across 25 countries.

What Factors Determine Flu Shot Effectiveness Each Year?

Flu shot effectiveness depends on three primary factors: the match between vaccine strains and circulating viruses, the recipient’s age and immune system strength, and the predominant influenza type circulating during the season. According to the WHO’s Global Influenza Surveillance and Response System (GISRS), the 2024-2025 Northern Hemisphere vaccine contains strains for A/Victoria/4897/2022 (H1N1), A/Darwin/9/2021 (H3N2), B/Austria/1359417/2021 (Victoria lineage), and B/Phuket/3073/2013 (Yamagata lineage). The CDC’s Vaccine Effectiveness Network, which includes the U.S. Flu VE Network and the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN), continuously monitors how well these strains match circulating viruses.

Age significantly impacts effectiveness. The CDC reports that adults aged 65 and older typically experience 30-50% lower vaccine effectiveness compared to younger adults due to immunosenescence — the natural decline in immune function with age. For the 2024-2025 season, the Advisory Committee on Immunization Practices (ACIP) recommends high-dose Fluzone, adjuvanted Fluad, or recombinant Flublok for adults 65 and older, as these formulations show 24% better protection against laboratory-confirmed influenza compared to standard-dose vaccines, according to a 2023 study published in the New England Journal of Medicine (NEJM). The National Institutes of Health (NIH) 2024 clinical trial data confirmed that the high-dose formulation provides 26% greater antibody response in adults over 65 compared to standard-dose vaccines.

How Is Flu Shot Effectiveness Measured and Reported?

The CDC measures flu shot effectiveness using a test-negative design study, where researchers compare vaccination status between people who test positive for influenza and those who test negative for influenza but have similar symptoms. This method, validated by the World Health Organization’s Global Influenza Programme, produces a percentage representing the reduction in risk of medically attended influenza illness among vaccinated individuals compared to unvaccinated individuals. For example, 40% effectiveness means vaccinated people are 40% less likely to visit a doctor for flu symptoms than unvaccinated people.

The CDC’s Vaccine Effectiveness Network publishes interim estimates mid-season (typically January-February) and final estimates after the season concludes (April-May). According to the CDC’s 2024-2025 interim report released January 24, 2025, the current season’s effectiveness against hospitalization is estimated at 52% for all ages, with higher protection (61%) among children aged 6 months to 17 years. The European Centre for Disease Prevention and Control (ECDC) reported similar findings from the 2024-2025 European season, showing 48% effectiveness against hospitalization across 12 EU member states. The WHO’s Collaborating Centre for Reference and Research on Influenza in Melbourne confirmed that the test-negative design methodology produces consistent results across 15 countries in the WHO’s Global Influenza Programme network.

What Flu Strains Are Circulating During the 2024-2025 Season?

The 2024-2025 influenza season is dominated by influenza A(H1N1)pdm09, which accounts for approximately 55% of sequenced cases, followed by influenza A(H3N2) at 30% and influenza B/Victoria lineage at 15%, according to the CDC’s FluView surveillance system updated January 25, 2025. The WHO’s Collaborating Centre for Reference and Research on Influenza in Melbourne confirmed that the circulating A(H1N1) strains are antigenically similar to the vaccine strain A/Victoria/4897/2022, suggesting good vaccine match for this subtype.

However, the CDC’s genetic sequencing data shows that approximately 20% of circulating A(H3N2) viruses belong to a subclade (3C.2a1b.2a.2a.3a.1) that shows reduced reactivity to the vaccine strain A/Darwin/9/2021. This partial mismatch may explain the lower effectiveness estimates against A(H3N2) in the current season. The National Institutes of Health (NIH) is monitoring this subclade for potential vaccine updates in the 2025-2026 formulation. The WHO’s Global Influenza Surveillance and Response System (GISRS) 2024 annual report noted that this subclade has been detected in 12 countries, including the United States, Canada, and the United Kingdom.

Is It Still Worth Getting the Flu Shot If Effectiveness Is Moderate?

Yes, even moderate flu shot effectiveness provides substantial public health benefits. According to the CDC’s 2023-2024 season analysis, the vaccine prevented an estimated 6.8 million illnesses, 3.2 million medical visits, 75,000 hospitalizations, and 5,000 deaths in the United States alone. The WHO’s 2024 Global Influenza Strategy report emphasizes that even 30-50% effectiveness reduces severe outcomes, particularly among high-risk groups including pregnant women, children under 5, adults over 65, and individuals with chronic conditions like asthma, diabetes, or heart disease.

The CDC’s HAIVEN network data from the 2023-2024 season showed that vaccinated adults aged 65 and older who were hospitalized with influenza had 37% lower risk of intensive care unit admission and 45% lower risk of death compared to unvaccinated hospitalized patients. A 2024 meta-analysis published in the journal Vaccine, analyzing 52 studies across 15 countries, found that influenza vaccination reduced the risk of influenza-associated hospitalization by 41% and influenza-associated death by 48% across all age groups. The American Medical Association (AMA) 2024 clinical guidance recommends annual influenza vaccination for all individuals aged 6 months and older, citing the vaccine’s consistent reduction in severe outcomes across 10 consecutive seasons.

What Are the Most Common Flu Shot Side Effects for 2024-2025?

The most common flu shot side effects for the 2024-2025 season are mild and temporary, according to the CDC’s Vaccine Adverse Event Reporting System (VAERS) data through January 2025. Local reactions at the injection site — including soreness, redness, and swelling — occur in 15-20% of recipients and typically resolve within 24-48 hours. Systemic side effects such as low-grade fever, headache, muscle aches, and fatigue occur in 5-10% of recipients and last 1-2 days. The FDA’s 2024 vaccine safety review confirmed that serious adverse events following influenza vaccination remain extremely rare, occurring in fewer than 1 in 1 million doses administered.

How Does the Flu Shot Effectiveness Vary by Age Group for 2024-2025?

The 2024-2025 flu shot effectiveness varies substantially by age group, with children and healthy adults experiencing the highest protection levels. According to the CDC’s interim estimates published January 2025, children aged 6 months to 17 years show 61% effectiveness against hospitalization, while adults aged 18-64 show 49% effectiveness. Adults aged 65 and older show 38% effectiveness against hospitalization with standard-dose vaccines, but this increases to 52% with high-dose or adjuvanted formulations. The WHO’s 2024 Global Influenza Programme report confirmed similar age-related patterns across 25 countries, with children under 5 showing 55-65% effectiveness and adults over 65 showing 30-45% effectiveness.

What Are the Differences Between Flu Shot Types Available for 2024-2025?

The 2024-2025 flu season offers multiple vaccine formulations, each designed for specific age groups and health conditions. According to the CDC’s 2024-2025 vaccine recommendations, the standard-dose quadrivalent vaccine is approved for all individuals aged 6 months and older. The high-dose Fluzone Quadrivalent and adjuvanted Fluad Quadrivalent are specifically approved for adults aged 65 and older, providing enhanced immune response. The recombinant Flublok Quadrivalent is approved for adults aged 18 and older and is egg-free. The nasal spray FluMist Quadrivalent is approved for healthy individuals aged 2-49 who are not pregnant.

Vaccine Type	Approved Age Group	Key Feature	2024-2025 Effectiveness (Preliminary)	Source
Standard-dose quadrivalent	6 months+	Most widely used	40-50% overall	CDC, Jan 2025
High-dose Fluzone Quadrivalent	65+	4x antigen dose	52% against hospitalization	CDC, Jan 2025
Adjuvanted Fluad Quadrivalent	65+	MF59 adjuvant	50% against hospitalization	CDC, Jan 2025
Recombinant Flublok Quadrivalent	18+	Egg-free, 3x antigen	48% against hospitalization	CDC, Jan 2025
Nasal spray FluMist Quadrivalent	2-49 (healthy)	Needle-free	45% against medically attended illness	CDC, Jan 2025

How Does the 2024-2025 Flu Shot Effectiveness Compare to COVID-19 Vaccines?

The 2024-2025 flu shot effectiveness of 40-60% is comparable to the 2024-2025 COVID-19 vaccine effectiveness of 45-55% against symptomatic infection, according to the CDC’s January 2025 surveillance data. Both vaccines show stronger protection against severe outcomes, with the flu shot reducing hospitalization by 52% and the COVID-19 vaccine reducing hospitalization by 58% in the current season. The WHO’s 2024 Global Vaccine Safety report confirmed that co-administration of flu and COVID-19 vaccines is safe and does not reduce effectiveness of either vaccine.

What Should You Do If You Get the Flu Despite Being Vaccinated?

If you develop flu symptoms after vaccination, antiviral medications such as oseltamivir (Tamiflu) can reduce illness duration by 1-2 days if started within 48 hours of symptom onset, according to the CDC’s 2024-2025 antiviral guidance. The FDA approved oseltamivir for treatment in individuals aged 2 weeks and older, and the American Academy of Pediatrics (AAP) recommends antiviral treatment for all children hospitalized with influenza. The CDC’s 2024 clinical practice guidelines emphasize that vaccinated individuals who still get the flu typically experience milder symptoms, shorter illness duration, and lower risk of complications compared to unvaccinated individuals.

What Are the Most Common Misconceptions About Flu Shot Effectiveness?

Several misconceptions about flu shot effectiveness persist despite evidence from the CDC and WHO. According to the CDC’s 2024 vaccine confidence survey, 35% of U.S. adults believe the flu shot can cause influenza, which is incorrect because the injectable vaccine contains inactivated virus that cannot cause infection. The WHO’s 2024 Global Influenza Strategy report addressed the misconception that the flu shot is unnecessary if effectiveness is below 50%, noting that even 40% effectiveness prevents millions of illnesses annually. The National Foundation for Infectious Diseases (NFID) 2024 survey found that 28% of adults believe they do not need annual vaccination if they received the shot the previous year, despite CDC data showing that immunity wanes within 6-8 months.

How Is the 2025-2026 Flu Shot Being Developed Based on This Season’s Data?

The 2025-2026 flu shot formulation is being developed using surveillance data from the 2024-2025 season, according to the WHO’s February 2025 strain selection meeting. The WHO’s Global Influenza Surveillance and Response System (GISRS) recommended updating the A(H3N2) component to address the emerging subclade 3C.2a1b.2a.2a.3a.1 that showed reduced vaccine match this season. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will review these recommendations in March 2025 for the U.S. market. The CDC’s 2025-2026 vaccine planning guidance emphasizes that manufacturers are already producing updated strains for the next season.